A Systematic Review of Safety and Immunogenicity of Influenza Vaccination Strategies in Solid Organ Transplant Recipients

Pearlie P. Chong, Lara Handler, David J. Weber

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

Immunogenicity from seasonal inactivated influenza vaccine (IIV) remains suboptimal in solid organ transplant recipients (SOTRs). We conducted a systematic review that compared the safety and immunogenicity of nonstandard influenza vaccination strategies with single-dose IIV in SOTRs. Booster doses and possibly high-dose (HD) influenza vaccination strategies seem to hold promise for improving vaccination immunogenicity in SOTRs. Administration of intradermal and MF59-adjuvanted trivalent IIV (IIV3) did not improve vaccine immunogenicity compared with single-dose intramuscular IIV. Alternative vaccine strategies were generally well tolerated; SOTRs who received HD, intradermal or adjuvanted IIV3 had a higher frequency of infection site reactions, while systemic adverse events were more frequent in SOTRs who received HD IIV3. Allograft rejection rates were similar in both groups. SOTRs should continue to receive standard-dose IIV annually in accordance with current recommendations, pending future studies to determine the optimal timing, frequency, and dosage of IIV using the booster-dose strategy.

Original languageEnglish (US)
Pages (from-to)1802-1811
Number of pages10
JournalClinical Infectious Diseases
Volume66
Issue number11
DOIs
StatePublished - May 17 2018

Fingerprint

Inactivated Vaccines
Influenza Vaccines
Human Influenza
Vaccination
Transplants
Safety
Allografts
Transplant Recipients
Vaccines
Infection

Keywords

  • immunization
  • immunogenicity
  • influenza vaccination
  • solid organ transplants

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

A Systematic Review of Safety and Immunogenicity of Influenza Vaccination Strategies in Solid Organ Transplant Recipients. / Chong, Pearlie P.; Handler, Lara; Weber, David J.

In: Clinical Infectious Diseases, Vol. 66, No. 11, 17.05.2018, p. 1802-1811.

Research output: Contribution to journalReview article

@article{428e70dbeff947b19814efe966689bc6,
title = "A Systematic Review of Safety and Immunogenicity of Influenza Vaccination Strategies in Solid Organ Transplant Recipients",
abstract = "Immunogenicity from seasonal inactivated influenza vaccine (IIV) remains suboptimal in solid organ transplant recipients (SOTRs). We conducted a systematic review that compared the safety and immunogenicity of nonstandard influenza vaccination strategies with single-dose IIV in SOTRs. Booster doses and possibly high-dose (HD) influenza vaccination strategies seem to hold promise for improving vaccination immunogenicity in SOTRs. Administration of intradermal and MF59-adjuvanted trivalent IIV (IIV3) did not improve vaccine immunogenicity compared with single-dose intramuscular IIV. Alternative vaccine strategies were generally well tolerated; SOTRs who received HD, intradermal or adjuvanted IIV3 had a higher frequency of infection site reactions, while systemic adverse events were more frequent in SOTRs who received HD IIV3. Allograft rejection rates were similar in both groups. SOTRs should continue to receive standard-dose IIV annually in accordance with current recommendations, pending future studies to determine the optimal timing, frequency, and dosage of IIV using the booster-dose strategy.",
keywords = "immunization, immunogenicity, influenza vaccination, solid organ transplants",
author = "Chong, {Pearlie P.} and Lara Handler and Weber, {David J.}",
year = "2018",
month = "5",
day = "17",
doi = "10.1093/cid/cix1081",
language = "English (US)",
volume = "66",
pages = "1802--1811",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "11",

}

TY - JOUR

T1 - A Systematic Review of Safety and Immunogenicity of Influenza Vaccination Strategies in Solid Organ Transplant Recipients

AU - Chong, Pearlie P.

AU - Handler, Lara

AU - Weber, David J.

PY - 2018/5/17

Y1 - 2018/5/17

N2 - Immunogenicity from seasonal inactivated influenza vaccine (IIV) remains suboptimal in solid organ transplant recipients (SOTRs). We conducted a systematic review that compared the safety and immunogenicity of nonstandard influenza vaccination strategies with single-dose IIV in SOTRs. Booster doses and possibly high-dose (HD) influenza vaccination strategies seem to hold promise for improving vaccination immunogenicity in SOTRs. Administration of intradermal and MF59-adjuvanted trivalent IIV (IIV3) did not improve vaccine immunogenicity compared with single-dose intramuscular IIV. Alternative vaccine strategies were generally well tolerated; SOTRs who received HD, intradermal or adjuvanted IIV3 had a higher frequency of infection site reactions, while systemic adverse events were more frequent in SOTRs who received HD IIV3. Allograft rejection rates were similar in both groups. SOTRs should continue to receive standard-dose IIV annually in accordance with current recommendations, pending future studies to determine the optimal timing, frequency, and dosage of IIV using the booster-dose strategy.

AB - Immunogenicity from seasonal inactivated influenza vaccine (IIV) remains suboptimal in solid organ transplant recipients (SOTRs). We conducted a systematic review that compared the safety and immunogenicity of nonstandard influenza vaccination strategies with single-dose IIV in SOTRs. Booster doses and possibly high-dose (HD) influenza vaccination strategies seem to hold promise for improving vaccination immunogenicity in SOTRs. Administration of intradermal and MF59-adjuvanted trivalent IIV (IIV3) did not improve vaccine immunogenicity compared with single-dose intramuscular IIV. Alternative vaccine strategies were generally well tolerated; SOTRs who received HD, intradermal or adjuvanted IIV3 had a higher frequency of infection site reactions, while systemic adverse events were more frequent in SOTRs who received HD IIV3. Allograft rejection rates were similar in both groups. SOTRs should continue to receive standard-dose IIV annually in accordance with current recommendations, pending future studies to determine the optimal timing, frequency, and dosage of IIV using the booster-dose strategy.

KW - immunization

KW - immunogenicity

KW - influenza vaccination

KW - solid organ transplants

UR - http://www.scopus.com/inward/record.url?scp=85047540929&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047540929&partnerID=8YFLogxK

U2 - 10.1093/cid/cix1081

DO - 10.1093/cid/cix1081

M3 - Review article

C2 - 29253095

AN - SCOPUS:85047540929

VL - 66

SP - 1802

EP - 1811

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 11

ER -